Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans

Autor: Verhaar, Marianne C, Grahn, Amy Y, van Weerdt, Anton W M, Honing, Marina L H, Morrison, Paul J, Yang, Yonghong P, Padley, Robert J, Rabelink, Ton J

Endothelins (ETs) may play a role in the pathogenesis of a variety of cardiovascular diseases. The present study was designed to investigate the pharmacokinetic and pharmacodynamic effects of the orally active ETA selective receptor antagonist ABT-62

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8072054cc39e880a544c644fc985bfc9
https://europepmc.org/articles/PMC2015037/

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans.

Autor: Honing MLH; Department of Vascular Medicine and Diabetes, University Hospital Utrecht, The Netherlands.; Clinical Pharmacology Unit, Utrecht, The Netherlands., Hijmering ML; Department of Vascular Medicine and Diabetes, University Hospital Utrecht, The Netherlands.; Clinical Pharmacology Unit, Utrecht, The Netherlands., Ballard DE; Abbott Laboratories, Abbott Park, Illinois., Yang YP; Abbott Laboratories, Abbott Park, Illinois., Padley RJ; Abbott Laboratories, Abbott Park, Illinois., Morrison PJ; Clinical Pharmacology Unit, Utrecht, The Netherlands., Rabelink TJ; Department of Vascular Medicine and Diabetes, University Hospital Utrecht, The Netherlands.

Publikováno v: Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2000 Aug; Vol. 11 (8), pp. 1498-1504.